Urgency to Expand SGLT2i Use in HF Heightened by More DELIVER Data
(MedPage Today) -- NATIONAL HARBOR, Md. -- The benefits of dapagliflozin (Farxiga) persisted in various secondary analyses of the DELIVER trial, building confidence for real-world benefits from the SGLT2 inhibitor for heart failure (HF) patients... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 3, 2022 Category: Cardiology Source Type: news
Obesity, Heart Failure, and SGLT2 Inhibition Obesity, Heart Failure, and SGLT2 Inhibition
A new analysis reveals that the SGLT2 inhibitor dapagliflozin produces a greater reduction in incident hospitalization for heart failure in obese patients compared with their non-obese counterparts.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Advances in Diabetes and Heart Disease From ESC 2022 Advances in Diabetes and Heart Disease From ESC 2022
The mortality risk of diabetes, the consistent efficacy of dapagliflozin, and adherence to SGLT2 inhibitors and GLP-1R agonists are some highlights from ESC 2022 chosen by Professor Pardeep Jhund.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 14, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
Stockholm Calls: Docs Eye New Tactics for Type 2 Diabetes at EASD Stockholm Calls: Docs Eye New Tactics for Type 2 Diabetes at EASD
New data on tirzepatide for weight loss and potential type 2 diabetes remission as well as an update on use of dapagliflozin for heart failure will be presented at the first in-person EASD meeting for 3 years.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 14, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Sep 2 2022 This Week in Cardiology Sep 2 2022 This Week in Cardiology
A second ESC review covering REVIVED, the DANCAVAS CV screening trial, DELIVER on dapagliflozin in HF with mildly reduced EF, and the INVICTUS trial of rivaroxaban in rheumatic heart disease.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 2, 2022 Category: Cardiology Tags: Cardiology Commentary Source Type: news
DELIVERing the Details on Dapagliflozin in Heart Failure DELIVERing the Details on Dapagliflozin in Heart Failure
Drs Pina and Solomon discuss the DELIVER trial presented at the European Society of Cardiology and whether all patients with heart failure should get SGLT2 inhibitors regardless of ejection fraction.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2022 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Dapagliflozin Cuts CV Risk in Heart Failure With Preserved LVEF
MONDAY, Aug. 29, 2022 -- For patients with heart failure with mildly reduced or preserved ejection fraction, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the combined risk for worsening heart failure or cardiovascular... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 29, 2022 Category: Pharmaceuticals Source Type: news
Finally, A Foundational Heart Failure Drug That Works Across the Spectrum of EF
(MedPage Today) -- BARCELONA -- With a major win in DELIVER, dapagliflozin (Farxiga) closed the gap on the types of heart failure (HF) proven to be treated safely by SGLT2 inhibition.
People with HF with preserved (HFpEF) and mildly reduced... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 28, 2022 Category: Cardiology Source Type: news
Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVER Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVER
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction-agnostic management approach.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 27, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Clinical Trial, Meta-Analysis Find Diabetes Drugs May Benefit All Heart Failure Patients
In a large-scale clinical trial, researchers from the Brigham found that dapagliflozin, an SGLT2 inhibitor, reduced the risk of cardiovascular death or worsening heart failure irrespective of ejection fraction; A meta-analysis also presented by Br (Source: BWH News)
Source: BWH News - August 26, 2022 Category: Hospital Management Source Type: news
Dapagliflozin Early Benefit Explored in Reduced-EF Heart Failure Dapagliflozin Early Benefit Explored in Reduced-EF Heart Failure
Why have SGLT2-inhibitor clinical benefits in HFrEF trials been evident so soon after the drugs are started? Recent studies shed light on one potential mechanism among what are probably many.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2022 Category: Consumer Health News Tags: Cardiology News Source Type: news
Dapagliflozin's HFpEF Win; Angiograms of the HIV+; Side Effects of PCSK9 Inhibitors?
(MedPage Today) -- For heart failure patients with mildly reduced or preserved ejection fraction in the DELIVER trial, dapagliflozin (Farxiga) helped reduce the risk of cardiovascular death and worsening heart failure, AstraZeneca announced, paving... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 10, 2022 Category: Cardiology Source Type: news
Positive Topline Results for Dapagliflozin in HFpEF: DELIVER Positive Topline Results for Dapagliflozin in HFpEF: DELIVER
AstraZeneca says regulatory submissions will be forthcoming, potentially bringing a second SGLT2 inhibitor in this space, after empagliflozin.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 5, 2022 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news
SGLT2 Inhibitor Safe for Kidneys in Hospitalized COVID Patients
(MedPage Today) -- Taking sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) didn't hinder renal outcomes for patients hospitalized with COVID-19, according to a secondary analysis of the DARE-19 trial.
Among patients with... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 29, 2022 Category: Cardiology Source Type: news
Dapagliflozin Well Tolerated in COVID-19 Patients, Regardless of eGFR
FRIDAY, April 29, 2022 -- The effects of dapagliflozin are similar for hospitalized patients with COVID-19 with estimated glomerular filtration rate (eGFR)<60 and≥60 mL/min per 1.73 m2, according to a study published online April 28 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 29, 2022 Category: Pharmaceuticals Source Type: news
